

Narikazu Boku

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3084082/publications.pdf>

Version: 2024-02-01

76
papers

7,042
citations

172207

29
h-index

82410

72
g-index

78
all docs

78
docs citations

78
times ranked

6907
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 2461-2471.	6.3	1,749
2	Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). <i>Lancet</i> , The, 2016, 388, 248-257.	6.3	799
3	Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 1640-1648.	0.8	548
4	Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. <i>Lancet Oncology</i> , The, 2009, 10, 1063-1069.	5.1	536
5	Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4438-4444.	0.8	439
6	Definitive Chemoradiotherapy for T4 and/or M1 Lymph Node Squamous Cell Carcinoma of the Esophagus. <i>Journal of Clinical Oncology</i> , 1999, 17, 2915-2915.	0.8	394
7	HER2-positive gastric cancer. <i>Gastric Cancer</i> , 2014, 17, 1-12.	2.7	272
8	Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 234-247.	5.1	268
9	A late phase II study of S-1 for metastatic pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 615-621.	1.1	156
10	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. <i>Gastric Cancer</i> , 2020, 23, 510-519.	2.7	155
11	Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. <i>Journal of Clinical Oncology</i> , 2021, 39, 966-977.	0.8	122
12	Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study). <i>Journal of Clinical Oncology</i> , 2020, 38, 1919-1927.	0.8	107
13	Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. <i>BMC Cancer</i> , 2019, 19, 974.	1.1	104
14	Randomized Phase III Trial of Adjuvant Chemotherapy with Gemcitabine versus S-1 in Patients with Resected Pancreatic Cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01). <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 227-229.	0.6	95
15	Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 501-510.	3.7	88
16	Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. <i>Cancer Treatment Reviews</i> , 2018, 66, 104-113.	3.4	78
17	Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104) Tj ETQq1 1 0.784314 rgBT /Overl <i>Hepatology</i> , 2019, 4, 208-216.	3.7	73
18	S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 99-108.	5.1	63

#	ARTICLE	IF	CITATIONS
19	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. <i>Gastric Cancer</i> , 2021, 24, 946-958.	2.7	61
20	Randomized study of <i>FOLFIRI</i> plus either panitumumab or bevacizumab for wild-type <i>KRAS</i> colorectal cancer— <i>WJOG</i> 6210G. <i>Cancer Science</i> , 2016, 107, 1843-1850.	1.7	60
21	A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). <i>Gastric Cancer</i> , 2019, 22, 344-354.	2.7	60
22	Determination of Prognostic Factors in Japanese Patients With Advanced Gastric Cancer Using the Data From a Randomized Controlled Trial, Japan Clinical Oncology Group 9912. <i>Oncologist</i> , 2014, 19, 358-366.	1.9	54
23	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2020, 23, 143-153.	2.7	45
24	Current status of immunotherapy for advanced gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 20-27.	0.6	43
25	Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities. <i>Nature Cancer</i> , 2021, 2, 962-977.	5.7	41
26	Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin. <i>Gastric Cancer</i> , 2009, 12, 206-211.	2.7	39
27	Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer. <i>ESMO Open</i> , 2019, 4, e000488.	2.0	39
28	S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1045-1056.	5.1	39
29	Phase I/II study of ramucirumab plus nivolumab in patients in second-line treatment for advanced gastric adenocarcinoma (NivoRam study).. <i>Journal of Clinical Oncology</i> , 2019, 37, 129-129.	0.8	32
30	A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: <i>WJOG7112G</i> (T-ACT).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4011-4011.	0.8	30
31	Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 981-989.	1.1	29
32	Efficacy of Postoperative Chemotherapy After Resection that Leaves No Macroscopically Visible Disease of Gastric Cancer with Positive Peritoneal Lavage Cytology (CY1) or Localized Peritoneum Metastasis (P1a): A Multicenter Retrospective Study. <i>Annals of Surgical Oncology</i> , 2020, 27, 284-292.	0.7	28
33	Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm. <i>Gastric Cancer</i> , 2018, 21, 429-438.	2.7	26
34	IL33 Is a Key Driver of Treatment Resistance of Cancer. <i>Cancer Research</i> , 2020, 80, 1981-1990.	0.4	24
35	Validation of the JCOG prognostic index in advanced gastric cancer using individual patient data from the SPIRITS and G-SOX trials. <i>Gastric Cancer</i> , 2017, 20, 757-763.	2.7	21
36	SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer. <i>Cancers</i> , 2019, 11, 187.	1.7	20

#	ARTICLE	IF	CITATIONS
37	Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design. <i>Future Oncology</i> , 2019, 15, 567-577.	1.1	20
38	Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies. <i>Molecular Carcinogenesis</i> , 2017, 56, 106-117.	1.3	19
39	Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective. <i>Gastric Cancer</i> , 2021, 24, 567-576.	2.7	19
40	A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 569-577.	1.1	16
41	The current status of multimodality treatment for unresectable locally advanced esophageal squamous cell carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 291-299.	0.7	16
42	Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer. <i>European Journal of Cancer</i> , 2020, 124, 67-76.	1.3	16
43	Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01). <i>European Journal of Cancer</i> , 2018, 93, 79-88.	1.3	14
44	Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 778-784.	2.7	13
45	Treatment Pattern for Advanced Gastric Cancer in Japan and Factors Associated with Sequential Treatment: A Retrospective Administrative Claims Database Study. <i>Advances in Therapy</i> , 2022, 39, 296-313.	1.3	13
46	Human equilibrative nucleoside transporter 1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy. <i>Cancer Science</i> , 2020, 111, 548-560.	1.7	12
47	Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 2. <i>International Journal of Clinical Oncology</i> , 2022, 27, 281-300.	1.0	11
48	Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 1. <i>International Journal of Clinical Oncology</i> , 2022, 27, 265-280.	1.0	11
49	Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study. <i>Gastric Cancer</i> , 2016, 19, 876-886.	2.7	10
50	Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials. <i>Journal of Clinical Oncology</i> , 2022, 40, e004273.		10
51	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. <i>Gastric Cancer</i> , 2022, 25, 207-217.	2.7	9
52	Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 575-582.	1.1	6
53	Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET study). <i>Pancreatology</i> , 2020, 20, 1183-1188.	0.5	6
54	Diagnosis of invasion depth in resectable advanced gastric cancer for neoadjuvant chemotherapy: An exploratory analysis of Japan clinical oncology group study: JCOG1302A. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1074-1079.	0.5	6

#	ARTICLE	IF	CITATIONS
55	Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer. <i>BMC Cancer</i> , 2020, 20, 338.	1.1	6
56	Surgical and perioperative treatment strategy for resectable esophagogastric junction cancer. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 417-424.	0.6	6
57	S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma. <i>Anticancer Research</i> , 2019, 39, 3931-3936.	0.5	5
58	Impact of peripheral neuropathy induced by platinum in first-line chemotherapy on second-line chemotherapy with paclitaxel for advanced gastric cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 595-601.	1.0	5
59	Prospective evaluation and refinement of an S ₁ dosage formula based on renal function for clinical application. <i>Cancer Science</i> , 2021, 112, 751-759.	1.7	5
60	Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer. <i>BMC Cancer</i> , 2021, 21, 1159.	1.1	5
61	Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study. , 2022, 10, e003518.		5
62	Second gastric cancer after curative endoscopic resection of differentiated-type early gastric cancer: post-hoc analysis of a single-arm confirmatory trial. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 650-659.	0.5	5
63	Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 107-116.	1.1	4
64	A Phase I study of pevonedistat plus capecitabine plus oxaliplatin in patients with advanced gastric cancer refractory to platinum (NCCH-1811). <i>Future Science OA</i> , 2021, 7, FSO721.	0.9	4
65	Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study. <i>Gastric Cancer</i> , 2021, , 1.	2.7	4
66	Temporal dynamics from phosphoproteomics using endoscopic biopsy specimens provides new therapeutic targets in stage IV gastric cancer. <i>Scientific Reports</i> , 2022, 12, 4419.	1.6	4
67	Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB). <i>JAMA Oncology</i> , 2022, 8, 929.	3.4	4
68	Selection of Second-line Anti-angiogenic Agents After Failure of Bevacizumab-containing First-line Chemotherapy in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 251-254.	1.0	3
69	Concordance of human equilibrative nucleoside transporter ¹ expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical outcomes of adjuvant chemotherapy for pancreatic cancer: A collaborative study from the JASPAC 01 trial. <i>Cancer Reports</i> , 2021, , e1507.	0.6	3
70	Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study. <i>Oncology</i> , 2019, 96, 309-317.	0.9	2
71	Primary Tumor-Related Complications Among Patients With Unresectable Stage IV Colorectal Cancer in the Era of Targeted Therapy: A Competing Risk Regression Analysis. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 1074-1082.	0.7	2
72	Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer. <i>PLoS ONE</i> , 2022, 17, e0269115.	1.1	2

#	ARTICLE	IF	CITATIONS
73	A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
74	Prediction of the peritoneal recurrence via the macroscopic diagnosis of the serosal invasion in patients with gastric cancer: Supplementary analysis of JCOG0110. <i>European Journal of Surgical Oncology</i> , 2022, , .	0.5	1
75	Evaluation of clinical validity of an S-1 dosage formula based on renal function using data of the SPIRITS and the G-SOX trials. <i>Gastric Cancer</i> , 2022, , 1.	2.7	1
76	Usefulness of an S-1 dosage formula: an exploratory analysis of randomized clinical trial (JCOG1001). <i>Gastric Cancer</i> , 0, , .	2.7	0